EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%
Gogishvili, M.; Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; ÖZGÜROĞLU, Mustafa; TÜRK, HACI MEHMET; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Gullo, G.; Lowy, I.; Rietschel, P.